Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 808–809 | Cite as

ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?

  • Mashaal Dhir
  • Amer H. ZureikatEmail author
ASO Author Reflections



The authors have no conflicts of interest to disclose.


  1. 1.
    Dhir M, Malhotra GK, Sohal DPS et al (2017) Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. World J Surg Onol 2017;15(1):183.CrossRefGoogle Scholar
  2. 2.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817–25.CrossRefGoogle Scholar
  3. 3.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369(18):1691–1703.CrossRefGoogle Scholar
  4. 4.
    Dhir M, Zenati MS, Hamad A, et al. FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma. Ann Surg Oncol 2018;25: 1896–1903.CrossRefGoogle Scholar
  5. 5.
    Sohal D, McDonough SL, Ahmad SA, et al. SWOG S1505: a randomized phase II study of perioperative mFOLFIRINOX versus gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 2018;36(4 suppl):TPS547.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Division of Surgical Oncology, Department of SurgerySUNY Upstate Medical UniversitySyracuseUSA
  2. 2.Division of Surgical Oncology, Department of SurgeryUniversity of Pittsburgh Medical CenterPittsburghUSA

Personalised recommendations